MYC and prostate carcinoma: Moreover, we found that treatment with 10058-F4, an inhibitor of c-Myc transcriptional activity, decreased the viability of enzalutamide-resistant (LNCaP-ENR) prostate cancer cells, documenting that the c-Myc activity plays an important role in the survival of ERPC cells (Fig. 1F).